Smith Group Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-160
| Closed | -$4K | – | 273 |
|
|
2021
Q4 | $4K | Hold |
160
| – | – | ﹤0.01% | 346 |
|
|
2021
Q3 | $3K | Buy |
+160
| New | +$3K | ﹤0.01% | 359 |
|
|
2020
Q3 | – | Sell |
-3,720
| Closed | -$180K | – | 307 |
|
|
2020
Q2 | $180K | Sell |
3,720
-60
| -2% | -$2.9K | 0.01% | 168 |
|
|
2020
Q1 | $160K | Sell |
3,780
-10
| -0.3% | -$423 | 0.01% | 182 |
|
|
2019
Q4 | $162K | Sell |
3,790
-300
| -7% | -$12.8K | 0.01% | 214 |
|
|
2019
Q3 | $147K | Buy |
4,090
+1,250
| +44% | +$44.9K | 0.01% | 211 |
|
|
2019
Q2 | $76K | Hold |
2,840
| – | – | ﹤0.01% | 253 |
|
|
2019
Q1 | $76K | Sell |
2,840
-8,800
| -76% | -$235K | ﹤0.01% | 275 |
|
|
2018
Q4 | $188K | Buy |
+11,640
| New | +$188K | 0.01% | 246 |
|
|
2016
Q2 | – | Sell |
-16,720
| Closed | -$467K | – | 471 |
|
|
2016
Q1 | $467K | Sell |
16,720
-150
| -0.9% | -$4.19K | 0.01% | 172 |
|
|
2015
Q4 | $601K | Buy |
+16,870
| New | +$601K | 0.02% | 198 |
|